Table 7.
Ongoing clinical trials on external-beam RT and Immune Checkpoint Inhibitors for patients with HCC.
| NCT Number | Institution | Phase | Disease | Intervention: ICI and Local Treatment | Estimated Enrollment | |
|---|---|---|---|---|---|---|
| 03482102 | MGH | II | Locally advanced/unresectable or metastatic diseaseHCC or biliary tract cancer | Tremelimumab + Durvalumab |
30 Gy/3 fx | 70 |
| 03203304 | UCh | I | HCC unresectable | Nivolumab | SBRT 40 Gy/5 fx |
50 |
| 03316872 | UHN | II | HCC showing progression after sorafenib |
Pembrolizumab | SBRT 5 fx |
30 |
| 03817736 | UHK | II | HCC prior hepatectomy | ICI | TACE + SBRT | 33 |
MGH: Massachusetts General Hospital; ICI: Immune Checkpoint Inhibitor; SBRT: Stereotactic Body Radiation Therapy; TACE: Trans-Arterial Chemo-Embolization; UCh: University of Chicago; UHN: University Health Network (Toronto); UHK: University of Hong Kong.